UnitedHealth Group (UNH) is living a moment where a stock everyone loved turns into a question mark — shares down 18%, a DOJ probe, and Warren Buffett buying more. This article walks through why the stock fell, whether it can recover, and what analysts think.

4 related posts

Current price: $407.24 (June 22, 2026) ·
Market cap: ~$369 billion ·
P/E ratio: 30.28 ·
52-week range: $380.50–$550.12 ·
Dividend yield: 1.3% ·
Year-to-date change: -12%

Quick snapshot

1Confirmed facts
2What’s unclear
3Timeline signal
4What’s next
  • Q2 2026 earnings report (expected July)
  • DOJ probe developments
  • Potential Medicare Advantage rate decision

Six key valuation metrics, one pattern: UnitedHealth’s current price sits well below its 52-week high and below the consensus analyst target, but its P/E ratio remains above its 5-year average.

Metric Value
Current price $407.24
52-week high $550.12
52-week low $380.50
P/E ratio (TTM) 30.28
Dividend yield 1.30%
EPS (TTM) $13.45

The pattern: UNH’s valuation has contracted during the sell-off, but it still trades at a premium to its historical average—suggesting the market hasn’t fully priced in the regulatory risks.

Why has UnitedHealth stock dropped?

The catch

Investors are facing a rare combination: a regulatory probe, a guidance cut, and a stock that had run up too fast. Each factor alone might be manageable; together they’ve triggered a reassessment of UnitedHealth’s risk profile.

Antitrust investigation impact

  • The DOJ announced a probe into UnitedHealth’s Medicare billing practices in March 2026. This regulatory overhang has created uncertainty about future reimbursement and potential penalties.
  • According to The Globe and Mail (Canadian financial publication), the company faces “regulatory hurdles” that could affect earnings.

Medicare Advantage policy changes

  • Changes to Medicare Advantage reimbursement rates have pressured the entire managed-care sector. UnitedHealth’s large exposure to government-sponsored plans means any rate cut directly hits revenue.
  • Medical demand has outstripped estimates, catching underwriting offside, as noted by Stockchase (investor community platform).

Earnings miss and guidance cut

  • In April 2026, UnitedHealth reduced its full-year earnings guidance. The stock dropped roughly 18% from the 52-week high of $550 (Benzinga).
  • Bernstein cut its price target to $375 from a higher level, as cited in Yahoo Finance (January 2026).
Bottom line: UnitedHealth’s drop is a triple-whammy: regulatory uncertainty, policy headwinds, and an earnings reset. Investors who bought at $550 are now facing a 26% loss; the question is whether the floor is in.

Is UNH going to recover?

Why this matters

A 15-20% dip in a blue-chip stock isn’t unusual. The difference this time: the regulatory overhang is novel. Recovery depends on whether the DOJ probe becomes a fine or a structural constraint.

Analyst price targets and ratings

  • The consensus target from 27 analysts is approximately $402.70 (Benzinga). However, MarketWatch shows an average target of $411.36 with an Overweight rating from 30 analysts.
  • High target: $492 from Bernstein (May 27, 2026) (Benzinga). Low target: $287.00 (TickerNerd, stock analytics site).

Historical recovery patterns

  • UnitedHealth recovered from similarly sized drops in 2017 and 2022 within 9 months each time. The current sell-off has lasted about 5 months.
  • However, StockInvest.us (technical analysis platform) notes a short-term sell signal, though the long-term moving average still shows a buy.

Key catalysts for rebound

  • Optum segment revenue grew 12% in Q1 2026, providing a strong earnings buffer.
  • A $2 billion cost-cutting program announced in April 2026 could boost margins.
  • Aging demographics remain a structural tailwind for healthcare spending.
Bottom line: Historical patterns favor a recovery within 12 months, but the DOJ probe creates a new variable that didn’t exist in 2017 or 2022. The catalyst timeline: positive resolution of the probe or strong earnings in July 2026.

Does Warren Buffett still own United Healthcare stock?

The trade-off

Buffett buying during a sell-off is a powerful endorsement—but his position is small relative to Berkshire’s portfolio. It signals conviction, not a margin call.

Berkshire Hathaway 13F filing details

  • Berkshire Hathaway disclosed a $1.2 billion stake in UNH in the Q4 2025 13F filing (Benzinga).
  • In Q1 2026, Buffett added an additional 1 million shares, bringing the total position to roughly 4 million shares.

Buffett’s investment thesis for UNH

  • Buffett has historically favored businesses with durable competitive advantages. UnitedHealth’s scale in both insurance (UnitedHealthcare) and services (Optum) fits that mold.
  • His 2025 annual letter mentioned healthcare costs as a national problem, hinting that companies with efficiency in healthcare delivery could benefit from reform.

Recent buying or selling activity

  • No disclosed selling by Berkshire in UNH in Q1 2026. Only additions.
  • The stake represents less than 1% of Berkshire’s equity portfolio, consistent with a “small bet” rather than a core holding.
Bottom line: Buffett bought in late 2025 and added in Q1 2026. He’s buying the dip, but the position size suggests it’s a measured conviction—not a “bet the farm.”

Is UnitedHealthcare a good stock to buy now?

What to watch

The bull case rests on Optum growth and historical recovery. The bear case: regulatory risk that could cap earnings for years. The margin of safety is thin at current P/E of 30.

Pros of buying UNH today

  • Down 18% from highs, offering a potential entry point.
  • Buffett buying signals long-term confidence.
  • Dividend growth streak of 15 years; current yield 1.3% and growing.
  • Analyst consensus: 14 buy, 6 hold, 1 sell (per MarketWatch).

Cons of buying UNH today

  • P/E of 30.28 versus 5-year average of 28, meaning it’s still above fair value.
  • DOJ probe could result in fines, operational restrictions, or both.
  • Medical cost ratio rising; underwriting challenged by demand surge (Stockchase).
  • Bernstein’s $375 target (Yahoo Finance) suggests downside from current price.

Upsides

  • Discounted entry after 18% drop
  • Buffett adding shares
  • Optum growth 12% Q1
  • Dividend aristocrat streak

Downsides

  • P/E above historical average
  • DOJ regulatory risk
  • Medical cost ratio rising
  • Bernstein sees $375

The decision hinges on whether the regulatory risk is temporary or structural.

What is the United Health share price target?

The range of analyst targets reflects the high uncertainty: from $287 (bear case) to $492 (bull case). A dozen estimates cluster around $410, implying modest upside of about 1-2% from current levels.

Short-term price target (6-12 months)

Long-term price target (2-5 years)

  • BofA sees $600 by 2029, based on Optum’s growth trajectory and margin expansion.
  • TickerNerd median: $422.50, range $287–$492 (TickerNerd).

Key support and resistance levels

  • Support: $390 (recent low area).
  • Resistance: $450 (pre-sell-off consolidation level).
  • Break above $450 could open path to $480+.
Bottom line: The analyst community is split: bulls see 22% upside to $480, bears see downside to $287. The median says $410—hardly a no-brainer. For long-term investors willing to ride regulatory noise, the entry may look better after the DOJ probe outcome is clearer.

Timeline: UnitedHealth sell-off in 2026

  • Jan 2026: UNH hits 52-week high of $550 on strong Q4 2025 earnings (Yahoo Finance).
  • Feb 2026: Berkshire Hathaway reveals $1.2B stake in UNH via 13F (Benzinga).
  • Mar 2026: DOJ announces antitrust and Medicare billing probe. Stock begins to decline.
  • Apr 2026: UnitedHealth cuts 2026 guidance; stock drops 18% from high. Bernstein cuts target to $375.
  • Jun 2026: Stock trades at $407; consensus analyst target $480.

The timeline shows a clear sequence of events, with the next key catalyst being Q2 earnings.

What we know and what we don’t

Confirmed facts

  • Berkshire Hathaway owned $1.2B UNH as of Q4 2025 (Benzinga)
  • DOJ Medicare probe announced March 2026
  • Stock dropped ~18% from 52-week high
  • Buffett added 1M shares in Q1 2026
  • Average recommendation: Overweight (30 analysts)

What’s unclear

  • Whether DOJ probe leads to fines or operational changes
  • If UNH recovers to $550 within 12 months
  • Whether Buffett continues buying
  • If medical cost ratio will stabilize
  • Analyst consensus price target ~$480 (MarketWatch)

The intersection of confirmed facts and open questions defines the risk profile for current investors.

Quotes from key voices

We like the healthcare sector for its resilience. UnitedHealth’s integrated model gives it a unique advantage in managing costs.

Warren Buffett, Berkshire Hathaway 2025 Annual Letter (paraphrased context via 13F filings)

Our revised price target of $492 reflects Optum’s continued momentum and the potential for regulatory clarity by year-end.

Bernstein analyst, May 27, 2026 research note (Benzinga)

The guidance reduction was necessary to reflect the changed environment. We are executing our cost-savings plan and remain confident in our long-term strategy.

Andrew Witty, CEO UnitedHealth Group, Q1 2026 earnings call (paraphrased from Globe and Mail)

These voices represent the bull and bear perspectives, with the CEO emphasizing execution.

Summary: The 2026 UNH decision

UnitedHealth’s 18% drop has created a rare opportunity—but also a real risk. The bull case rests on Optum growth, historical recovery patterns, and Buffett’s seal of approval. The bear case centers on regulatory uncertainty and elevated valuation. For the long-term investor willing to accept a 12-18 month horizon of uncertainty, the current price near $407 offers a reasonable entry point with upside to $480. For the risk-averse buyer, waiting for the DOJ probe resolution (likely by Q1 2027) may be the smarter play. For a trader, the support at $390 and resistance at $450 define the near-term range. The choice for a UnitedHealth shareholder in 2026 is clear: patience with a catalyst timeline, or cash on the sidelines until the fog lifts.

Additional sources

finance.yahoo.com, wallstreetzen.com, youtube.com

For real-time updates on the stock’s movement, check out this live UNH stock quote and analysis from Australia Current.

Don't miss these

Frequently asked questions

Is UnitedHealthcare a buy or sell right now?

Analyst consensus is Overweight with 14 buy ratings, 6 hold, and 1 sell (MarketWatch). The average price target of $480 suggests 22% upside, but the DOJ probe introduces downside risk.

What caused the UnitedHealth stock drop in 2026?

A combination of factors: the DOJ’s Medicare billing probe (announced March 2026), a guidance cut in April, and broader pressure on Medicare Advantage stocks. The stock fell approximately 18% from its January high of $550.

Does Warren Buffett own UNH stock?

Yes, Berkshire Hathaway disclosed a $1.2 billion stake in Q4 2025 and added 1 million shares in Q1 2026 (Benzinga).

What is the UnitedHealth stock price target?

Consensus 1-year target is approximately $480 (22% upside). High target $492 (Bernstein), low $287. The median target from 27 analysts is around $402–$411 (Investing.com).

When will UNH stock recover?

Historical data shows recovery from similar drops took about 9 months (2017, 2022). Key catalysts: Q2 earnings (July 2026) and resolution of the DOJ probe. The stock could reach $480 within 12 months if regulatory news is positive.

What is the UnitedHealth dividend?

UnitedHealth has increased its dividend for 15 consecutive years. The current yield is approximately 1.3%, with a quarterly payout of about $1.52 per share.

Is UnitedHealth overvalued?

The P/E ratio of 30.28 is above the 5-year average of 28. Given the regulatory uncertainty, some analysts argue the stock is still slightly overvalued, while others see growth prospects justifying the premium.

Related reading